RxDoctor Payments Data

Wendy Henderson, NP

Family · Wartburg, TNNPI 1407232689

Payments from drug & device makers

$1,786in general payments, 2019–2025

Across 85 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$329
  • Teva Pharmaceuticals USA, Inc.$299
  • GSK$211
  • Novo Nordisk$192
  • Phathom Pharmaceuticals, Inc.$164
  • Otsuka America Pharmaceutical, Inc.$125
  • plus $466 from 15 others

What the payments were for

  • Food & beverage$1,786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,786 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,371
Medicare patients
25
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$38,274
JanuviaSitagliptin Phosphate31$36,863
MounjaroTirzepatide23$35,073
OzempicSemaglutide27$27,811
Spiriva HandihalerTiotropium Bromide25$20,073
EliquisApixaban25$19,844
Tresiba Flextouch U-200Insulin Degludec13$10,475
JentaduetoLinagliptin/Metformin Hcl12$6,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,461
Albuterol Sulfate HfaAlbuterol Sulfate106$2,706
Gabapentin183$2,131
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen52$1,763
Omeprazole101$1,750
Lidocaine16$1,711
Atorvastatin Calcium151$1,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$211$38,27433 claims
Lilly USA, LLCMounjaro$18$35,07323 claims
Novo NordiskOzempic$192$27,81127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Wartburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →